Exploration of the putative role of cannabinoid dysregulation in the pathogenesis of atopic dermatitis (Bíró lab)

Team leader: Attila Oláh, MD, PhD
Participants: Arnold Markovics MSc, Judit Szabó-Papp, MSc, Fanni Kinga Tóth, MSc
Collaborative partners:
Lajos Kemény, MD, PhD, DSc (University of Szeged, Szeged, Hungary)
Ilona Kovács, MD, PhD (Gyula Kenézy Hospital, Debrecen, Hungary)
Prof. Jürg Gertsch (University of Bern, Bern, Switzerland)
Prof. Amos Gilhar (Technion Israel Institute of Technology, Haifa, Israel)
Prof. Dr. Ralf Paus (University of Manchester, Manchester, UK)
Dr. August Wolff GmbH & Co. KG Arzneimittel (Bielefeld, Germany)

Eczema, a.k.a. atopic dermatitis (AD) is an extremely prevalent inflammatory cutaneous disease, which is characterized by dryness, severe itching and scratching of designated skin areas. AD is especially common in childhood; therefore, it is obvious that exploration of new, easy-to-apply, effective, but still side-effect-free tools to treat this disease must be among the top priorities in experimental dermatology research.

According to our own previous results as well as to the available data of the literature, investigation of the so-called “cutaneous cannabinoid system” appears to be a very promising, new direction in AD research. Cannabinoid system plays complex physiological regulatory roles, controlling not only inflammation, but also the development of the protective cutaneous barrier. In light of all these, within the confines of the current study, we aim to explore role of this putative cannabinoid dysregulation in the pathogenesis of AD, which holds out the promise to develop new medications acting through the modulation of the cannabinoid system.